Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The Medical business reported higher revenue and profit, supported by expanded sales of the “Mighty” series, growth in the subscription model and M&A. The Technology Consulting business reported lower revenue and profit because it prioritized limiting orders for small-scale, short-term projects, reviewing low-margin projects and developing AI talent in preparation for the transition to AI-driven development. Meanwhile, operating profit at the Philippine subsidiary increased as a result of optimizing pricing, restructuring its cost base and expanding direct-contract projects, primarily in the United States.
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥5,992 million (YoY -5.5%) |
| Operating profit | ¥1,304 million (YoY -0.9%) |
| Ordinary income | ¥1,287 million (YoY -4.0%) |
| Profit attributable to owners of the parent | ¥891 million (YoY +3.9%) |
| Net income per share | ¥73.56 |
| Operating Margin | 21.8% |
| Equity ratio | End of the current fiscal period 75.5% / End of previous period 70.4% |
| Total assets | ¥7,975 million |
| Net assets | ¥6,025 million |
| Cash flows from operating activities | ¥984 million |
| Cash flows from investing activities | ¥-57 million |
| Cash flows from financing activities | ¥-627 million |
| Cash and cash equivalents at end of period | ¥5,166 million |
| Full-year earnings forecast | Net Sales ¥7,383 million (YoY +23.2%) / Operating profit ¥1,511 million (YoY +15.9%) / Ordinary income ¥1,520 million (YoY +18.1%) / Net income ¥1,056 million (YoY +18.4%) |
| Annual Dividend Forecast | ¥40 → Undecided（Undecided） |
| Payout ratio | 54.4% |
| Segment revenue | Technology Consulting Business ¥4,043.47 million (YoY -12.4%), Medical Business ¥1,949.10 million (YoY +13.1%) |
| Segment profit | Technology Consulting Business ¥430.78 million (YoY -23.4%), Medical Business ¥1,226.76 million (YoY +8.7%) |
| Regional sales | ¥5,014.39 million, ¥413.27 million, ¥287.77 million, ¥117.31 million, ¥159.83 million |
| Depreciation and amortization | ¥178,765 thousand |
| Impairment loss | No applicable matters. |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of investment securities ¥53,301 thousand, Gain on sale of non-current assets ¥635 thousand, Gain on negative goodwill ¥2,222 thousand / Extraordinary loss Loss on Disposal of Fixed Assets ¥200 thousand, Impairment Loss on Investment Securities ¥49,919 thousand |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 1 / Company name 株式会社ISM / Excluded Number of companies 0 / Company name Not disclosed |
| Material subsequent events | On 1 April 2026, the company acquired 100% of the common shares of ラジエンスウエア株式会社 and made it a subsidiary. The purchase consideration was ¥649,000 thousand, and acquisition-related expenses were ¥75,652 thousand. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors and analysts |
| Issued Shares at Period-End | 12,249,920 shares |
| Treasury Shares at Period-End | 126,679 shares |
| Factors Behind Changes in Business Performance | The Medical business reported higher revenue and profit, supported by expanded sales of the “Mighty” series, growth in the subscription model and M&A. The Technology Consulting business reported lower revenue and profit because it prioritized limiting orders for small-scale, short-term projects, reviewing low-margin projects and developing AI talent in preparation for the transition to AI-driven development. Meanwhile, operating profit at the Philippine subsidiary increased as a result of optimizing pricing, restructuring its cost base and expanding direct-contract projects, primarily in the United States. |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the Medical business, results benefited from expanded sales of the “Mighty” series, accumulated subscription revenue and M&A. In the Technology Consulting business, revenue and operating profit declined as the company prioritized the transition to future AI-driven development by limiting orders for small-scale, short-term projects, reviewing low-margin projects and developing AI talent. M&A-related expenses for ラジエンスウエア株式会社 were also recorded.